Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance

Although proteasome inhibition with bortezomib (BTZ) is a validated treatment for relapsed or refractory mantle cell lymphoma (MCL), many patients show resistance to BTZ. However, the molecular mechanism of BTZ resistance in MCL has not been elucidated. In the present study, we investigated BTZ-resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Areumnuri, Seong, Ki Moon, Kang, Hye Jin, Park, Sunhoo, Lee, Seung-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741995/
https://www.ncbi.nlm.nih.gov/pubmed/26517678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741995/
https://www.ncbi.nlm.nih.gov/pubmed/26517678

Ejemplares similares